Introduction
As many as 10% of all leukemias have abnormalities of the short arm of chromosome 12 (abn 12p). The 12p aberrations include translocations, deletions, [del(12p)], inversions, dicentric and derived, [der(12p)]. chromosomes. Reciprocal translocations between 12p and a number of other chromosomal bands have been identified by karyotypic analysis. Partner chromosome bands include: 1p13, 2p11, 2q11, 3q26, 5q33, 7q11, 9p11, 11q23, 13q14, 14q11, 16q13, 17p11, 17q21, 20q11 and 22q12. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] To date, the only gene shown to be involved in 12p rearrangements is the ETV6 gene located at band 12p13. 1, 2 This gene is a member of the ETS gene family of DNA binding proteins that recognise the core motifs C/AGGAA/T.
14 ETV6 was first identified as the fusion partner of the PDGFR␤ gene in the translocation t(5;12)(q33;p12) in a patient with chronic Correspondence: L Foroni; Fax: 171 794 0645 Received 19 January 1998; accepted 26 March 1998 myelomonocytic leukemia (CMML).
1 It now appears that ETV6 is a 'promiscuous' gene disrupted by fusion with one of many partner genes. Fusion of the ETV6 gene to the MN1 gene located on chromosome 22q11 has been shown in myelopproliferative disorders (MPD). 4 The ETV6 gene has also been shown to fuse with the ABL gene (on 9q34) in a patient with t (9;12;14) and acute undifferentiated leukemia. 3 Recently, translocations involving ETV6 have been reported in patients with myelodysplastic syndrome and a t(3;12)(q26;p13). 15 Preliminary reports of fusion products cloned by rapid amplification of cDNA ends (RACE-PCR) have described fusions in which exons 1, or exons 1 and 2 of ETV6, were fused to the EVI1 gene on chromosome 3. Fusion of ETV6 and AML1 is brought about by t(12;21), 2, 11 a translocation that cannot be detected by classic cytogenetic analysis. This genetic rearrangement has been described in B-lineage acute lymphoblastic leukemia (ALL) with an incidence of 16-30% in childhood 2, 10, 16, 17 and of 3% in adults with ALL. 18, 19 Patients with this translocation have been shown to have a good prognosis. 16, [20] [21] [22] Twenty patients with cytogenetically detectable 12p abnormalities were analyzed for rearrangements/deletions of the ETV6 gene. We have developed a novel one-step exonspecific RT-PCR assay to investigate ETV6 rearrangements and to identify the exons adjoining the breakpoint.
Materials and methods

Patient data
Patients in the study had c/pre-B ALL (nine children and three adults), T-ALL (three adults), acute myeloid leukemia (AML) (two adults), biphenotypic acute leukemia (Bip-L) (one adult), myelodysplasia (MDS) (one adult) and chronic myelomonocytic leukemia (CMML) (one child). Children were aged between 3 and 11 years and adults were aged between 17 and 53 years. The age, sex, diagnosis, karyotype and fluorescence in situ hybridization (FISH) results for each patient are shown in Table 1 .
Cytogenetic and FISH analysis
Cytogenetic analysis had been carried out following 24-h culture, using standard techniques. Karyotypes were described according to ISCN. 23 In 10 cases, FISH using chromosomespecific, whole chromosome paints (wcp) was applied to clarify the 12p abnormality.
Nucleic acid extraction DNA was extracted from bone marrow (unseparated or mononuclear cell fractions) using a method previously described. RNA was isolated after guanidine thiocyanate disruption of the cells, followed by caesium chloride gradient separation 25 or acid phenol extraction. 26 RT-PCR analysis for ETV6 rearrangement Development of exon-specific RT-PCR analysis Bone marrow cDNA was synthesized from 2 g of total RNA as previously described. 25 One twentieth of the reaction (5 l cDNA) was submitted to PCR amplification in 50 l with 250 ng primers, 0.2 mM dNTPs and 2.5 U of Taq (Life Technologies, Inchinnan, UK) in the buffer recommended by the supplier. To prevent false negative results all cDNA preparations were verified by amplification of G6PD as previously described. 25 Forward and reverse primers for exons 1 to 8 of the ETV6 gene were used in six simultaneous RT-PCR reactions to amplify across the exons of the ETV6 cDNA as illustrated in Figure 1a . Figure 1b shows the nucleotide sequence of the primers used.
A break in any intron of ETV6 as a result of a translocation will interrupt the continuity of the exon organisation. This will result in a reduction/failure in amplification of products when using primers for exons flanking the breakpoint region. However, exons upstream of the breakpoint itself will still amplify as the ETV6 promoter remains functional. 1, 11 Exons downstream of the breakpoint will amplify if the reciprocal product is expressed. Primers were designed to have comparable annealing temperatures and to amplify products of similar size. As a result, given the small size of exons 1, 2 and 3, rearrangements in introns 1, 2 and 3 were identified by amplification between exons 1 and 2, 1 and 3, and 1 and 4, respectively. Rearrangements in introns 6 and 7 were identified by amplification between exons 6 and 8. Amplification between exons 6 and 8 would not distinguish between rearrangements in introns 6 and 7. Consequently, a further primer to exon 7 could be used to identify the breakpoint in intron 6 or 7.
Accurate assessment of a reduction in band intensity brought about by a translocation was achieved following a series of tests. Each primer pair was first tested with 1, 2.5 and 5 l cDNA from normal bone marrow using between 25 and 35 cycles. For each primer pair semi-quantitative results were obtained using 30 cycles (data not shown). Thirty cycles were sufficient for all patient samples except cases 2 and 19, which required 28 and 32 cycles, respectively. All reactions were carried out using a denaturation step at 94°C for 5 min followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 64°C for 1 min and extension at 72°C for 1 min with a final extension at 72°C for 10 min. PCR products were electrophoresed through a 1.5% agarose gel, containing 1 l/ml ethidium bromide and photographed under UV light. All tests were performed at least three times for each patient to ensure consistent and reproducible results.
RT-PCR analysis for ETV6/AML1 fusion RNA prepared from bone marrow was investigated for the ETV6/AML1 fusion by RT-PCR. The primers used were: ETF5; CTC CGA GGA CGG GCT GCA TAG GGA AGG (bp 900-927) specific to ETV6 exon 5 and AML3; AAG AGC TCG CTC ATC TTG CCT GG (bp 833-855) for exon 2 of the AMLI gene. 
3′ RACE PCR
This procedure was carried out as described by the 3′ RACE PCR protocol supplied with the kit (Life Technologies) with the following modifications: the primer used to generate the cDNA contained random hexamers at the 3′ end as opposed to dT (5′ GGC CAC GCG TCG ACT AGT ACT nnn nnn 3′). In the first round PCR, only the gene-specific primer (GSP) 5Fb (5′ GGG AGA CTA GGA CTT GGG GGC CGT GAG G 3′) were used with the following PCR conditions: 30 cycles of 1 min denaturation at 94°C, 1 min annealing at 64°C and 2.5 min extension at 72°C. This was completed by a final 10 min extension at 72°C. In the second round PCR both the internal GSP 5Fa: (5′ TAG GAA TCC GAG GCT CCT GCC CGA CGT ATC CCT TCC CTT C 3′) and the RACE PCR primer (5′ GGC CAC GCG TCG ACT AGT AC 3′) were used with the following PCR conditions: an initial denaturation of 5 min at 94°C followed by 30 cycles of, 1 min denaturation at 94°C, 1 min annealing at 64°C and 2 min extension at 72°C. This was completed by a final 10 min extension at 72°C. The PCR products were cleaned and digested with the restriction enzymes EcoRI and SalI. The digested products were electrophoresed on a 1.5% agarose gel. PCR products between 400-600 bp were isolated, cloned into the plasmid pBSK+ and sequenced.
Southern blot analysis of ETV6
DNA samples (10 g) were digested to completion with the enzymes EcoRI, HindIII, BamHI or SacI. The restricted DNA was size fractionated on a 0.8% agarose gel and visualized by ethidium bromide staining. Following transfer to Hybond-N membranes (Amersham, Buckinghamshire, UK) using standard Southern blotting techniques, 27 filters were hybridized at 65°C using a dextran sulphate-based hybridization buffer. 24 Probes were labelled to high specific activity by random hexanucleotide priming (Amersham) with ␣-32 P-dCTP. Filters were washed at 65°C for 20 min in 0.3 × SSC, 0.1% SDS with one change of buffer. 28 Southern analysis was used, where possible, to confirm the data from the exon-specific RT-PCR assay and to detect heterozygosity to a polymorphic site in ETV6 and hence allelic deletion. For this reason two cDNA and two genomic probes for intron 5 were used, as described below.
Probes for Southern blotting
RT-PCR amplification from normal BM cDNA was used to generate the 5′ and 3′ ETV6 cDNA probes. Amplification was carried out using primers 1F and 8B (Figure 1b ) with denaturation at 94°C for 1 min, 66°C annealing for 1 min and extension at 72°C for 2 min. A 1.3 kb band was cloned and sequenced. The 5′ subclone containing exons 2-5 (bp 136 to bp 675 according to the published sequence 1 was generated by digestion with XhoI and SacI. The 3′ subclone containing exons 5-8 (bp 672 to bp 1383) was generated by digestion with the same enzymes (XhoI artificially introduced at the 3′ end). The cDNA probes would only identify rearrangements which occurred close to exon boundaries, ie on the same restricted fragment as the exon. Two genomic probes (B1 and D) which map to intron 5 of ETV6 were used. These were a kind gift from Dr R Berger, Paris, and have been previously described. 17 The genomic probe, B1 was used with EcoRI digests to detect heterozygosity for an EcoRI polymorphism and hence to detect ETV6 deletions.
17
Results
Cytogenetic analysis
Abnormalities of 12p detected by G-banding and by FISH analysis, when available are shown in Table 1 . From cytogenetic analysis, del(12p) was seen as the sole abnormality in seven cases and accompanied by an abnormality of the second 12p in one case. Five cases had a balanced translocation of 12p with partner sites at 1p13, 14p11, 10q11, 1q31 and 15q15. The remaining seven cases had an add(12p) indicative of an unbalanced translocation of 12p which could not be fully described. FISH, using whole chromosome paints (wcp) to 12 and 21, was applied in five cases and showed fusion between chromosomes 12 and 21 in four cases; a balanced translocation t(12;21) was shown in cases 2 and 3 and an unbalanced translocation, der(12)t(12;21), in case 4. In case 6, due to limited material, FISH with wcp 12 only was applied and the result suggested der(21)t(12;21). The use of whole chromosome paints identified the der(12p) partner in three cases as chromosome 1 (case 3), chromosome 3 (case 6), and chromosome 11 (case 4) and confirmed the partner chromosome as 14 and 10 in cases 8 and 10, respectively.
RT-PCR analysis for ETV6 rearrangement
Control bone marrow from hematologically healthy individuals, using the combination of primers illustrated in Figure 1a and listed in Figure 1b , showed six bands of equal intensity (Figure 2a) . RT-PCR analysis was carried out in 19 of 20 patients (case 17 had insufficient material for this study and was not investigated). In nine patients a reduction in one of the RT-PCR-amplified products was seen indicating a breakpoint within ETV6 (Figure 2b-d) . Breakpoints were localized within the ETV6 gene to intron 5 in seven patients, (cases 1-4 and 6-8), to intron 2 (case 19), and to intron 4 (case 20)
Figure 2
RT-PCR analysis of the ETV6 gene using cDNA from bone marrow of patients with 12p rearrangements. RT-PCR analysis of the ETV6 gene using cDNA from bone marrow of patients with 12p rearrangements. A, control; B, patient 20; C, patient 7; D, patient 19; and E, patient 8. Each bands results from PCR amplification across two exons as indicated. In Figure 2b , amplification has failed between exons 4-5 suggesting that a rearrangement has occurred in intron 4 in patient 20. In Figure 2c the band resulting from the amplification between exons 5 and 6 is reduced suggesting that the organisation of the ETV6 gene was disrupted within intron 5 in patient 7. In patient No. 19, a reduction in the intensity of amplification was observed between exons 1-3 and exons 1-4 ( Figure 2d ) while amplification between exons 1 and 2 was normal, thus suggesting a breakpoint in intron 2. A reduction in amplification between exons 5-6 and 6-7 was observed in patient 8 (Figure 2e) suggesting the presence of a breakpoint in intron 5 and a lack of expression of the reciprocal product containing ETV6 exons 6 and 7.
( Table 1) . A normal pattern was detected in the remaining 10 patients (cases 5, 9-16, 18).
Investigation of the t(12;21) ETV6/AML1
ETV6/AML1 rearrangements were detected, using previously published primers 17 in five out of 19 patients investigated (cases 1-5). A sixth case (case 6), had an alternative spliced form of ETV6/AML1 fusion detected using 3′ RACE PCR (figure 3). In this patient, the ETB6 exon 5 was fused in frame to AML1 alternative exon 2 which was then spliced to exon 5 ( Figure 3) . No product was obtained upon repeated RT-PCR amplification using the conventional primers in this patient.
The remaining 18 patients were tested for this newly identified fusion form but were found to be negative. Five of the six patients with ETV6/AML1 fusion had been found to have rearrangements in intron 5, the sixth case, however had been normal by exon specific RT-PCR. ETV6/AML1 fusion product in patient 6. 3′ RACE PCR amplification using primers described in the Materials and methods indicated the presence of a fusion between exon 5 of ETV6 and exon 2 of AML1. A splice between exon 2 and exon 5 of AML1 is suggested by sequence analysis of the clones obtained. Primers derived from this sequence were used for PCR amplification on patient's material and the expected size fragment was obtained. No other patient tested in this series shows this type of alternative ETV6/AML1 product.
Southern blot analysis for rearrangement of ETV6
Southern blots with the enzyme BamHI were available for 16 patients, of these 11 patients also had either EcoRI or SacI Southern blots. Southern blotting confirmed rearrangement of intron 5 in five available cases which had shown intron 5 involvement by exon-specific PCR (cases 1, 3, 6, 7 and 8) (Figure 4 ). In addition, Southern blotting showed a rearrangement in intron 5 in case 11 which had been normal on exonspecific PCR. In this case, the intensity of the rearranged fragment was less than that of the germ-line fragment, suggesting that rearrangement had occurred in a minor clone and consequently it would have been undetectable by the RT-PCR assay ( Figure 5 ). Rearrangements in these six cases were identified using BamHI digests. In five cases the rearrangement was seen with the genomic probe B1, but not with the genomic probe D which suggested that a small deletion of intronic region had occurred during the genomic rearrangements. In one remaining case (case 8) the rearrangement was identified only by the cDNA probes indicating that this deletion also included the region covered by probe B1. Deletion of the germ-line allele was suggested by the presence of a faint germ-line band relative to the rearranged band and was detected in two cases with ETV6 rearrangement (cases 3 and 6). However in the remaining three cases (cases 1, 7 and 8), the rearranged band was of equal or slightly less intensity than the germ-line band suggesting ETV6 was present on the untranslocated allele, or the deletion had occurred in a very small percentage of cells. No rearrangements were identified elsewhere in the gene but this did not exclude rearrangements in other introns of ETV6 as the probes used only covered a small portion of the ETV6 gene. No rearrangements were seen in cases 19 and 20 due to lack of available probes to introns 2 and 4. In four patients (Nos 2, 4, 5 and 13) insufficient material was available for Southern blot analysis.
Deletion of ETV6 detected by EcoRI/SacI for B1 RFLP
Our analysis indicated that the RFLP identified by the probe B1 occurred in 50% of hematologically healthy individuals and patients tested (data not shown). Seven of 11 patients tested were heterozygous for the B1 site (5.5 kb and 6.5 kb on the SacI or EcoRI digest). In four patients reduction of the 5.5 kb band (cases 11 and 15-17) suggested deletion of one allele ( Figure 6 ). Three of these patients had cytogenetically detectable deletions of 12p (cases 11, 15 and 17), while case 16 had add (12) .
Abnormalities of 12p and rearrangements of ET6 shown by exon-specific RT-PCR, by RT-PCR for ETV6/AML1 fusion or by Southern blotting to exon 5 or by B1 heterozygosity In summary, rearrangements of the ETV6 gene were shown in 11/19 cases with abn 12p. These abnormalities were identified by G-banding as partial arm deletions only (three cases), as balanced translocations (four cases) or as translocations of 12p which could not be fully described, ie add(12p) (four cases). Nine patients had rearrangements in intron 5 of which six carried the ETV6/AML1 fusion product. Discrepancies between the molecular methods were seen in two cases. Case 5 was positive for the ETV6/AML1 fusion but had not shown rearrangement with exon-specific RT-PCR and case 11 showed rearrangement by Southern blotting only. Cases 7, 8 and 11 showed rearrangements in intron 5 which were not due to ETV6/AML1 fusion. The possibility that one allele of ETV6 might be deleted was investigated in the seven cases which were polymorphic using the B1 probe. Four of these showed a deletion of the 5.5 kb band. In total, six patients had a deletion of ETV6, three of which also had a rearrangement of the gene.
Discussion
The detection of chromosomal abnormalities and subsequent identification of aberrant fusion genes in leukemia is important for diagnosis and patient management. The detailed molecular analysis of patients with hematological malignancy and a clonal abnormality of the short arm of chromosome 12 presented here has revealed a marked association of this karyotypic abnormality with abnormalities of the ETV6 gene. This study indicates that rearrangement of the ETV6 gene in the bone marrow may be as high as 60%. This incidence compares with that reported by Sato et al 29 who described ETV6 rearrangements in 12/23 patients with 12p abnormalities. In our patient group, rearrangements of ETV6 were most frequent in children with c-ALL where eight of nine children had a rearrangement in intron 5 of ETV6. In particular the ETV6-AML1 fusion was present in 67% of children with c-ALL. The incidence of the ETV6-AML1 fusion in childhood B-lineage ALL in an unselected series of childhood cases has been between 15 and 30%. 10, 16, 17 Our study suggests that this cryptic translocation occurs predominantly in association with a cytogenetically detectable abnormality of 12p. None of the adults with ALL had the ETV6-AML1 fusion in this study.
The exon-specific RT-PCR analysis enables rearrangements to be detected anywhere within the gene and in addition indicates where the breakpoint has occurred. The assay enabled identification of rearrangements in patients where no small 
Figure 5
Southern blot analysis of the ETV6 gene in patient with 12p deletions. Southern analysis of genomic DNA digested with BamHI from controls and patients 2 and 11 probed with B1 which contains sequence of intron 5. Rearrangements are detected in two patients with deletions of 12p cytogenetically. In one patient (case 11) the rearranged band was markedly fainter than the germ-line band suggesting that the arrangement occurs in a minor clone.
deletion of the other ETV6 allele was detected by Southern analysis. However in two cases, a rearrangement which was identified by ETV6AML1 RT-PCR or Southern blotting was not detected by exon-specific RT-PCR. This is probably due to the size of the clone, detection of which would be beyond the sensitivity limits of the assay. In such cases FISH analysis would be more effective in detecting rearrangements. Breakpoints were concentrated in intron 5 (seven of nine positive Southern blot analysis to identify ETV6 deletions in patients who are heterozygous for an EcoRI/SacI polymorphism. Southern blot analysis of the ETV6 gene in patients with 12p rearrangements. Total human DNA digested with SacI and probed with the polymorphic probe B1. Note the two bands which occur in 50% of cases. The patient (case 17) with a deletion of one ETV6 gene is arrowed.
cases) as previously reported. 7, 30 Patients with breakpoints in intron 2 and intron 4 of ETV6 were also identified in this study. Fusions between ETV6 introns 2 and 4 and the MN1 gene and the PDGFR␤ gene in patients with t(12;22) and t(5;12), respectively, have also been described. 1, 4 A breakpoint in intron 1 had also been reported. 15 Investigation by RT-PCR using conventional primers for the presence of ETV6-AML1 fusion, revealed the fusion in four of the seven patients with a breakpoint in intron 5 of ETV6 and in a fifth patient in whom no breakpoint had been detected by the exon-specific approach. A possible explanation for the discrepancy would be the presence of the fusion gene in a minor clone, as discussed above. A sixth patient had an alternative spliced fusion, detected by 3′ RACE PCR, which was unique in our series of patients. In this transcript, exon 5 of ETV6 is fused to AMLI exon 5 as opposed to exon 3. FISH analysis using whole chromosome paints, when available, identified a translocation t(12;21) in patients with ETV6-AML1 as expected. Evidence from FISH analysis indicated that both homologues of chromosome 12 were structurally changed in two of four cases tested and that the cryptic t(12;21) translocation had occurred on the cytogenetically normal 12p. These cases (Nos 1 and 6) also had a translocation of 12p to chromosome 1, and to chromosome 3, respectively. Two further cases had translocations between chromosomes 12 and 21, and 12 and 11 or 14 (cases 4 and 8) but there was insufficient evidence to discover whether both homologues of chromosome 12 were involved or whether a three-way translocation resulting in ETV6/AML1 fusion had occurred. Cases with both t(12;21) and ins(12;1) or (3;12) showed a marked reduction in the germline ETV6 allele on Southern blot analysis indicating that the translocation of 12p to chromosomes 1 and 3 was each accompanied by a deletion of ETV6 (cases 3 and 6, respectively). In a further patient carrying the ETV6/AML1 fusion (case 2), the rearranged band detected by Southern analysis was weaker than the germline band. This does not preclude the possibility that a deletion of ETV6 had occurred in a minor clone which would be undetectable by Southern analysis. In these cases, FISH analysis would be more productive in detecting any deletions. Deletion of the second allele in cases with t(12;21) has been reported. 10 Two children with c-ALL were shown to have a breakpoint in intron 5 but not to have the ETV6-AMLI fusion. In these patients, a translocation of 12p with 1p13 and 14q11, respectively, had been demonstrated. Neither has previously been described in association with ETV6 but they form likely candidate sites for novel fusion genes. Both these cases are being further investigated for possible fusion partners to ETV6. In one of these cases, FISH analysis had shown a derived 21 containing DNA from chromosome 12 but this did not appear to be reciprocal. This raises the possibility that genes other than ETV6 and AML1 may be important in some cases.
Two adults, one with acute biphenotypic leukemia and one with acute myeloid leukemia, with a translocation of 12p13 to 1q31 and 15q15 showed breakpoints in intron 2 and intron 4, respectively. These two locations are therefore candidate sites for new fusion partners to ETV6. The identification of ETV6 rearrangements, using exon-specific RT-PCR, conventional RT-PCR analysis and Southern blotting to exon 5, were concordant in all but two cases. Failure to detect a rearrangement by the exon-specific method in each case may have been explained by the presence of a relatively small clone below the level of detection by RT-PCR.
An attempt was made to look for deletions of ETV6 alleles in patients heterozygous for the B1 site. Among seven of the informative cases, three had a reduced amount of the 5.5 kb homologue indicating deletion. These were found in one patient with add(12p) and in three patients with cytogenetically visible del(12p). In these three cases the cytogenetic evidence indicated that the region deleted was considerably greater than that covered by a single gene and the relevance of this gene loss in these cases is therefore uncertain. Studies on loss of heterozygosity have described deletion of one ETV6 allele in 5-20% of ALL patients. The region of loss, however, included not only ETV6 but also the gene KIP1 and possibly other as yet unknown genes. 31, 32 The target gene(s) for these deletions is as yet unidentified. Two further deletions were detected in patients who had rearrangements.
It has been suggested that ETV6 is a 'promiscuous' gene and FISH analysis using single copy probes has revealed a number of other translocations of ETV6 with a variety of chromosome bands including 10q24, 9p23, Xq28 and 1q21 and 6q23. [33] [34] [35] The translocation t(9;12) has led to the identification of a novel fusion in which the HLH domain of ETV6 is fused to the JAK2 kinase in ALL and AML. 36, 37 Our findings confirm that ETV6 may be involved in translocations with a number of other chromosomes; 1p13, 1q31, 14q11 and 15q15. The five patients with novel ETV6 rearrangements will be analyzed using RACE-PCR in an attempt to clone novel partner genes.
